Research advances in primary biliary cholangitis
10.3969/j.issn.1001-5256.2016.11.009
- VernacularTitle:原发性胆汁性胆管炎的研究进展
- Author:
Weijia DUAN
1
;
Qiuju TIAN
;
Hong YOU
Author Information
1. Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
- Publication Type:Research Article
- Keywords:
liver cirrhosis;
biliary;
diagnosis;
therapy
- From:
Journal of Clinical Hepatology
2016;32(11):2062-2065
- CountryChina
- Language:Chinese
-
Abstract:
Primary biliary cholangitis is a chronic intrahepatic cholestatic liver disease and has increasing incidence and prevalence rates, as is reported in the literature. Examination of specific antibodies including serum anti-mitochondrial antibody subtype M2 and liver histopathological examination help to make a definite diagnosis of this disease. Ursodeoxycholic acid (UDCA) is often used for the treatment of this disease, but patients with an unsatisfactory biochemical response to UDCA tend to have rapid disease progression. At present, there are no effective treatment methods for such patients. The addition of budesonide, fenofibrate, bezafibrate, or obeticholic acid may be effective in these patients, but this needs to be verified by further clinical studies.
